Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region
The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in the EMBRAZE region. The test identifies which patients are suited for standard cancer treatments, and which patients could benefit from experimental treatments. EMBRAZE is a cancer care network in the provinces of North Brabant and Zeeland.
More information
You read an article in the category Billing code. You may also be interested in Cancer of Unknown Primary, OncoAct or Participating hospitals.All news
Also read
Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be …
New cancer treatment options created by full DNA-analysis
Nature publication reports study by Netherlands Center for Personalized Cancer Treatment showing benefits for targeted treatments outside registered indications 2 …
Ten years of Hartwig Medical Foundation: a retrospect and a glimpse of the future
In its first decade, Hartwig Medical Foundation has made significant progress towards its goal of providing access to all diagnostic …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.